Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Prothena ( (PRTA) ).
On May 23, 2025, Prothena Corporation announced that its Phase 3 AFFIRM-AL clinical trial for birtamimab in AL amyloidosis patients did not meet its primary or secondary endpoints, leading to the discontinuation of birtamimab’s development. As a result, Prothena plans to reduce operating expenses, including a significant workforce reduction, and will provide further updates in June. Despite the setback, Prothena remains focused on its other pipeline projects, including upcoming data from the Phase 1 ASCENT trials on PRX012 in Alzheimer’s disease and updates from its partners.
The most recent analyst rating on (PRTA) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.
Spark’s Take on PRTA Stock
According to Spark, TipRanks’ AI Analyst, PRTA is a Neutral.
Prothena’s overall stock score reflects the company’s challenges with profitability and cash flow despite revenue growth and strong partnerships. The technical analysis indicates a bearish trend, while the valuation shows the typical high-risk, high-reward scenario of a biotech firm heavily reliant on clinical success. The earnings call highlighted strategic strengths but also underscored the critical need for clinical achievements to drive future growth.
To see Spark’s full report on PRTA stock, click here.
More about Prothena
Prothena Corporation plc is a clinical-stage biotechnology company specializing in protein dysregulation with a focus on developing investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates for conditions such as ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, and Parkinson’s disease.
Average Trading Volume: 909,050
Technical Sentiment Signal: Sell
Current Market Cap: $352.6M
See more data about PRTA stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue